APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nanocarrier-Based Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Nanocarrier-Based Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025186 pages

Choose your research edition.

Industry ResearchNanocarrier-Based Vaccine Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Nanocarrier-Based Vaccine Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Nanocarrier-Based Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nanocarrier-Based Vaccine Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Nanocarrier-Based Vaccine Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Nanocarrier-Based Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Nanocarrier-Based Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nanocarrier-Based Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nanocarrier-Based Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Nanocarrier-Based Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Nanocarrier-Based Vaccine include Emergent BioSolutions, GlaxoSmithKline Biologicals, Moderna, Pfizer, Merck, Novartis and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Nanocarrier-Based Vaccine market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nanocarrier-Based Vaccine and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nanocarrier-Based Vaccine revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Nanocarrier-Based Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Nanocarrier-Based Vaccine Segment by Company

Emergent BioSolutions

GlaxoSmithKline Biologicals

Moderna

Pfizer

Merck

Novartis

Sanofi

Nanocarrier-Based Vaccine Segment by Type

Adjuvants

Delivery Systems

Nanocarrier-Based Vaccine Segment by Application

Hospital

Clinic

Other

Nanocarrier-Based Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nanocarrier-Based Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nanocarrier-Based Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nanocarrier-Based Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Nanocarrier-Based Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nanocarrier-Based Vaccine industry.

Chapter 3: Detailed analysis of Nanocarrier-Based Vaccine companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nanocarrier-Based Vaccinerevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Adjuvants Table 3. Key Players of Delivery Systems Table 4. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Hospital Table 6. Key Players of Clinic Table 7. Key Players of Other Table 8. Global Nanocarrier-Based Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 9. Global Nanocarrier-Based Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 10. Global Nanocarrier-Based Vaccine Market Share by Region (2021-2026) Table 11. Global Nanocarrier-Based Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 12. Global Nanocarrier-Based Vaccine Market Share by Region (2027-2032) Table 13. Nanocarrier-Based Vaccine Industry Trends Table 14. Nanocarrier-Based Vaccine Industry Drivers Table 15. Nanocarrier-Based Vaccine Industry Opportunities and Challenges Table 16. Nanocarrier-Based Vaccine Industry Restraints Table 17. Global Nanocarrier-Based Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 18. Global Nanocarrier-Based Vaccine Revenue Market Share by Company (2021-2026) Table 19. Global Nanocarrier-Based Vaccine Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 20. Global Nanocarrier-Based Vaccine Key Company Head Office and Area Served Table 21. Global Nanocarrier-Based Vaccine Company, Product Type & Application Table 22. Global Nanocarrier-Based Vaccine Company Establishment Date Table 23. Global Company Market Concentration Ratio (CR5 and HHI) Table 24. Global Nanocarrier-Based Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 25. Global Nanocarrier-Based Vaccine Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Nanocarrier-Based Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 27. Global Nanocarrier-Based Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 28. Global Nanocarrier-Based Vaccine Revenue Market Share by Type (2021-2026) Table 29. Global Nanocarrier-Based Vaccine Revenue Market Share by Type (2027-2032) Table 30. Global Nanocarrier-Based Vaccine Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Nanocarrier-Based Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 32. Global Nanocarrier-Based Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 33. Global Nanocarrier-Based Vaccine Revenue Market Share by Application (2021-2026) Table 34. Global Nanocarrier-Based Vaccine Revenue Market Share by Application (2027-2032) Table 35. Emergent BioSolutions Company Information Table 36. Emergent BioSolutions Business Overview Table 37. Emergent BioSolutions Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Emergent BioSolutions Nanocarrier-Based Vaccine Product Portfolio Table 39. Emergent BioSolutions Recent Development Table 40. GlaxoSmithKline Biologicals Company Information Table 41. GlaxoSmithKline Biologicals Business Overview Table 42. GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Product Portfolio Table 44. GlaxoSmithKline Biologicals Recent Development Table 45. Moderna Company Information Table 46. Moderna Business Overview Table 47. Moderna Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Moderna Nanocarrier-Based Vaccine Product Portfolio Table 49. Moderna Recent Development Table 50. Pfizer Company Information Table 51. Pfizer Business Overview Table 52. Pfizer Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Pfizer Nanocarrier-Based Vaccine Product Portfolio Table 54. Pfizer Recent Development Table 55. Merck Company Information Table 56. Merck Business Overview Table 57. Merck Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Merck Nanocarrier-Based Vaccine Product Portfolio Table 59. Merck Recent Development Table 60. Novartis Company Information Table 61. Novartis Business Overview Table 62. Novartis Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Novartis Nanocarrier-Based Vaccine Product Portfolio Table 64. Novartis Recent Development Table 65. Sanofi Company Information Table 66. Sanofi Business Overview Table 67. Sanofi Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Sanofi Nanocarrier-Based Vaccine Product Portfolio Table 69. Sanofi Recent Development Table 70. North America Nanocarrier-Based Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 71. North America Nanocarrier-Based Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 72. North America Nanocarrier-Based Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 73. North America Nanocarrier-Based Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 74. North America Nanocarrier-Based Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 75. North America Nanocarrier-Based Vaccine Market Size by Country (2021-2026) Table 76. North America Nanocarrier-Based Vaccine Market Size by Country (2027-2032) Table 77. Europe Nanocarrier-Based Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 78. Europe Nanocarrier-Based Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 79. Europe Nanocarrier-Based Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 80. Europe Nanocarrier-Based Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 81. Europe Nanocarrier-Based Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. Europe Nanocarrier-Based Vaccine Market Size by Country (2021-2026) Table 83. Europe Nanocarrier-Based Vaccine Market Size by Country (2027-2032) Table 84. China Nanocarrier-Based Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 85. China Nanocarrier-Based Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 86. China Nanocarrier-Based Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 87. China Nanocarrier-Based Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 88. Asia Nanocarrier-Based Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 89. Asia Nanocarrier-Based Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 90. Asia Nanocarrier-Based Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 91. Asia Nanocarrier-Based Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 92. Asia Nanocarrier-Based Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. Asia Nanocarrier-Based Vaccine Market Size by Country (2021-2026) Table 94. Asia Nanocarrier-Based Vaccine Market Size by Country (2027-2032) Table 95. South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Type (2021-2026) & (US$ Million) Table 96. South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Type (2027-2032) & (US$ Million) Table 97. South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Application (2021-2026) & (US$ Million) Table 98. South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Application (2027-2032) & (US$ Million) Table 99. South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2021-2026) Table 101. South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2027-2032) Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Nanocarrier-Based Vaccine Product Image Figure 2. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Nanocarrier-Based Vaccine Market Share by Type: 2025 VS 2032 Figure 4. Adjuvants Image Figure 5. Delivery Systems Image Figure 6. Global Nanocarrier-Based Vaccine Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global Nanocarrier-Based Vaccine Market Share by Application: 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Other Image Figure 11. Global Nanocarrier-Based Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 13. Global Nanocarrier-Based Vaccine Market Share by Region: 2025 VS 2032 Figure 14. Years Considered Figure 15. Global Nanocarrier-Based Vaccine Market Share by Players in 2025 Figure 16. Global Top 5 and 10 Nanocarrier-Based Vaccine Players Market Share by Revenue in 2025 Figure 17. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Nanocarrier-Based Vaccine Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Nanocarrier-Based Vaccine Revenue Market Share by Type (2021-2032) Figure 20. Global Nanocarrier-Based Vaccine Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Nanocarrier-Based Vaccine Revenue Market Share by Application (2021-2032) Figure 22. North America Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 23. North America Nanocarrier-Based Vaccine Market Share by Type (2021-2032) Figure 24. North America Nanocarrier-Based Vaccine Market Share by Application (2021-2032) Figure 25. North America Nanocarrier-Based Vaccine Market Share by Country (2021-2032) Figure 26. United States Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 27. Canada Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 28. Mexico Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 29. Europe Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 30. Europe Nanocarrier-Based Vaccine Market Share by Type (2021-2032) Figure 31. Europe Nanocarrier-Based Vaccine Market Share by Application (2021-2032) Figure 32. Europe Nanocarrier-Based Vaccine Market Share by Country (2021-2032) Figure 33. Germany Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 34. France Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 35. U.K. Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 36. Italy Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 37. Russia Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 38. Nordic Countries Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 39. China Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 40. China Nanocarrier-Based Vaccine Market Share by Type (2021-2032) Figure 41. China Nanocarrier-Based Vaccine Market Share by Application (2021-2032) Figure 42. Asia Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 43. Asia Nanocarrier-Based Vaccine Market Share by Type (2021-2032) Figure 44. Asia Nanocarrier-Based Vaccine Market Share by Application (2021-2032) Figure 45. Asia Nanocarrier-Based Vaccine Market Share by Country (2021-2032) Figure 46. Japan Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 47. South Korea Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 48. Taiwan Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 49. Southeast Asia Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 50. India Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 51. Australia Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 53. South America, Middle East & Africa Nanocarrier-Based Vaccine Market Share by Type (2021-2032) Figure 54. South America, Middle East & Africa Nanocarrier-Based Vaccine Market Share by Application (2021-2032) Figure 55. South America, Middle East & Africa Nanocarrier-Based Vaccine Market Share by Country (2021-2032) Figure 56. Brazil Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 57. South Africa Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 58. Saudi Arabia Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 59. Turkey Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 60. Argentina Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 61. UAE Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 62. Egypt Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 63. Chile Nanocarrier-Based Vaccine Market Size (2021-2032) & (US$ Million) Figure 64. Research Process Figure 65. Key Executives Interviewed

Scope & coverage.

Types
  • Adjuvants
  • Delivery Systems
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Emergent BioSolutions
  • GlaxoSmithKline Biologicals
  • Moderna
  • Pfizer
  • Merck
  • Novartis
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Nanocarrier-Based Vaccine Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Adjuvants
  5. 1.2.3 Delivery Systems
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global Nanocarrier-Based Vaccine Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Other
  11. 1.4 Global Market Growth Prospects
  12. 1.5 Global Nanocarrier-Based Vaccine Growth Trends by Region
  13. 1.5.1 Global Nanocarrier-Based Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  14. 1.5.2 Nanocarrier-Based Vaccine Market Size by Region (2021-2026)
  15. 1.5.3 Nanocarrier-Based Vaccine Market Size by Region (2027-2032)
  16. 1.6 Assumptions and Limitations
  17. 1.7 Study Goals and Objectives
  18. 1.8 Years Considered
2 Global Nanocarrier-Based Vaccine Market Dynamics
  1. 2.1 Nanocarrier-Based Vaccine Industry Trends
  2. 2.2 Nanocarrier-Based Vaccine Industry Drivers
  3. 2.3 Nanocarrier-Based Vaccine Industry Opportunities and Challenges
  4. 2.4 Nanocarrier-Based Vaccine Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Nanocarrier-Based Vaccine Revenue by Company (2021-2026)
  2. 3.2 Global Nanocarrier-Based Vaccine Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Nanocarrier-Based Vaccine Key Company Head office and Area Served
  4. 3.4 Global Nanocarrier-Based Vaccine Company, Product Type & Application
  5. 3.5 Global Nanocarrier-Based Vaccine Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Nanocarrier-Based Vaccine Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Nanocarrier-Based Vaccine Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Nanocarrier-Based Vaccine Tier 1, Tier 2, and Tier 3
4 Nanocarrier-Based Vaccine Market by Type
  1. 4.1 Global Nanocarrier-Based Vaccine Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Nanocarrier-Based Vaccine Market Size by Type (2021-2032)
  3. 4.3 Global Nanocarrier-Based Vaccine Market Size Share by Type (2021-2032)
5 Nanocarrier-Based Vaccine Market by Application
  1. 5.1 Global Nanocarrier-Based Vaccine Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Nanocarrier-Based Vaccine Market Size by Application (2021-2032)
  3. 5.3 Global Nanocarrier-Based Vaccine Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Emergent BioSolutions
  2. 6.1.1 Emergent BioSolutions Company Information
  3. 6.1.2 Emergent BioSolutions Business Overview
  4. 6.1.3 Emergent BioSolutions Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Emergent BioSolutions Nanocarrier-Based Vaccine Product Portfolio
  6. 6.1.5 Emergent BioSolutions Recent Developments
  7. 6.2 GlaxoSmithKline Biologicals
  8. 6.2.1 GlaxoSmithKline Biologicals Company Information
  9. 6.2.2 GlaxoSmithKline Biologicals Business Overview
  10. 6.2.3 GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 GlaxoSmithKline Biologicals Nanocarrier-Based Vaccine Product Portfolio
  12. 6.2.5 GlaxoSmithKline Biologicals Recent Developments
  13. 6.3 Moderna
  14. 6.3.1 Moderna Company Information
  15. 6.3.2 Moderna Business Overview
  16. 6.3.3 Moderna Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Moderna Nanocarrier-Based Vaccine Product Portfolio
  18. 6.3.5 Moderna Recent Developments
  19. 6.4 Pfizer
  20. 6.4.1 Pfizer Company Information
  21. 6.4.2 Pfizer Business Overview
  22. 6.4.3 Pfizer Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Pfizer Nanocarrier-Based Vaccine Product Portfolio
  24. 6.4.5 Pfizer Recent Developments
  25. 6.5 Merck
  26. 6.5.1 Merck Company Information
  27. 6.5.2 Merck Business Overview
  28. 6.5.3 Merck Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Merck Nanocarrier-Based Vaccine Product Portfolio
  30. 6.5.5 Merck Recent Developments
  31. 6.6 Novartis
  32. 6.6.1 Novartis Company Information
  33. 6.6.2 Novartis Business Overview
  34. 6.6.3 Novartis Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Novartis Nanocarrier-Based Vaccine Product Portfolio
  36. 6.6.5 Novartis Recent Developments
  37. 6.7 Sanofi
  38. 6.7.1 Sanofi Company Information
  39. 6.7.2 Sanofi Business Overview
  40. 6.7.3 Sanofi Nanocarrier-Based Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Sanofi Nanocarrier-Based Vaccine Product Portfolio
  42. 6.7.5 Sanofi Recent Developments
7 North America
  1. 7.1 North America Nanocarrier-Based Vaccine Market Size (2021-2032)
  2. 7.2 North America Nanocarrier-Based Vaccine Market Size by Type
  3. 7.2.1 North America Nanocarrier-Based Vaccine Market Size by Type (2021-2026)
  4. 7.2.2 North America Nanocarrier-Based Vaccine Market Size by Type (2027-2032)
  5. 7.2.3 North America Nanocarrier-Based Vaccine Market Share by Type (2021-2032)
  6. 7.3 North America Nanocarrier-Based Vaccine Market Size by Application
  7. 7.3.1 North America Nanocarrier-Based Vaccine Market Size by Application (2021-2026)
  8. 7.3.2 North America Nanocarrier-Based Vaccine Market Size by Application (2027-2032)
  9. 7.3.3 North America Nanocarrier-Based Vaccine Market Share by Application (2021-2032)
  10. 7.4 North America Nanocarrier-Based Vaccine Market Size by Country
  11. 7.4.1 North America Nanocarrier-Based Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Nanocarrier-Based Vaccine Market Size by Country (2021-2026)
  13. 7.4.3 North America Nanocarrier-Based Vaccine Market Size by Country (2027-2032)
  14. 7.4.4 North America Nanocarrier-Based Vaccine Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Nanocarrier-Based Vaccine Market Size (2021-2032)
  2. 8.2 Europe Nanocarrier-Based Vaccine Market Size by Type
  3. 8.2.1 Europe Nanocarrier-Based Vaccine Market Size by Type (2021-2026)
  4. 8.2.2 Europe Nanocarrier-Based Vaccine Market Size by Type (2027-2032)
  5. 8.2.3 Europe Nanocarrier-Based Vaccine Market Share by Type (2021-2032)
  6. 8.3 Europe Nanocarrier-Based Vaccine Market Size by Application
  7. 8.3.1 Europe Nanocarrier-Based Vaccine Market Size by Application (2021-2026)
  8. 8.3.2 Europe Nanocarrier-Based Vaccine Market Size by Application (2027-2032)
  9. 8.3.3 Europe Nanocarrier-Based Vaccine Market Share by Application (2021-2032)
  10. 8.4 Europe Nanocarrier-Based Vaccine Market Size by Country
  11. 8.4.1 Europe Nanocarrier-Based Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Nanocarrier-Based Vaccine Market Size by Country (2021-2026)
  13. 8.4.3 Europe Nanocarrier-Based Vaccine Market Size by Country (2027-2032)
  14. 8.4.4 Europe Nanocarrier-Based Vaccine Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Nanocarrier-Based Vaccine Market Size (2021-2032)
  2. 9.2 China Nanocarrier-Based Vaccine Market Size by Type
  3. 9.2.1 China Nanocarrier-Based Vaccine Market Size by Type (2021-2026)
  4. 9.2.2 China Nanocarrier-Based Vaccine Market Size by Type (2027-2032)
  5. 9.2.3 China Nanocarrier-Based Vaccine Market Share by Type (2021-2032)
  6. 9.3 China Nanocarrier-Based Vaccine Market Size by Application
  7. 9.3.1 China Nanocarrier-Based Vaccine Market Size by Application (2021-2026)
  8. 9.3.2 China Nanocarrier-Based Vaccine Market Size by Application (2027-2032)
  9. 9.3.3 China Nanocarrier-Based Vaccine Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Nanocarrier-Based Vaccine Market Size (2021-2032)
  2. 10.2 Asia Nanocarrier-Based Vaccine Market Size by Type
  3. 10.2.1 Asia Nanocarrier-Based Vaccine Market Size by Type (2021-2026)
  4. 10.2.2 Asia Nanocarrier-Based Vaccine Market Size by Type (2027-2032)
  5. 10.2.3 Asia Nanocarrier-Based Vaccine Market Share by Type (2021-2032)
  6. 10.3 Asia Nanocarrier-Based Vaccine Market Size by Application
  7. 10.3.1 Asia Nanocarrier-Based Vaccine Market Size by Application (2021-2026)
  8. 10.3.2 Asia Nanocarrier-Based Vaccine Market Size by Application (2027-2032)
  9. 10.3.3 Asia Nanocarrier-Based Vaccine Market Share by Application (2021-2032)
  10. 10.4 Asia Nanocarrier-Based Vaccine Market Size by Country
  11. 10.4.1 Asia Nanocarrier-Based Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Nanocarrier-Based Vaccine Market Size by Country (2021-2026)
  13. 10.4.3 Asia Nanocarrier-Based Vaccine Market Size by Country (2027-2032)
  14. 10.4.4 Asia Nanocarrier-Based Vaccine Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Nanocarrier-Based Vaccine Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst